Cwm LLC Has $684,000 Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Cwm LLC lifted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 471.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,722 shares of the company’s stock after buying an additional 19,571 shares during the quarter. Cwm LLC’s holdings in Apellis Pharmaceuticals were worth $684,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Iron Triangle Partners LP bought a new stake in Apellis Pharmaceuticals in the first quarter valued at $32,329,000. Fiera Capital Corp increased its stake in Apellis Pharmaceuticals by 47.7% in the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares in the last quarter. AQR Capital Management LLC increased its stake in Apellis Pharmaceuticals by 337.3% in the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Redmile Group LLC bought a new stake in Apellis Pharmaceuticals in the first quarter valued at $9,111,000. Finally, Senator Investment Group LP bought a new stake in Apellis Pharmaceuticals in the first quarter valued at $8,229,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $28.00 on Friday. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -8.09 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. Apellis Pharmaceuticals, Inc. has a 52 week low of $26.28 and a 52 week high of $73.80. The firm’s 50-day simple moving average is $34.16 and its two-hundred day simple moving average is $39.62.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.02) earnings per share. As a group, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on APLS. HC Wainwright reduced their price objective on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a “neutral” rating for the company in a report on Friday, September 20th. UBS Group reduced their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Friday, September 20th. Finally, Scotiabank began coverage on shares of Apellis Pharmaceuticals in a report on Wednesday. They set a “sector outperform” rating and a $35.00 price objective for the company. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.00.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).